Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series

[1]  J. Wetzels,et al.  Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy. , 2014, Clinical journal of the American Society of Nephrology : CJASN.

[2]  E. Rhee,et al.  Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis. , 2014, Clinical journal of the American Society of Nephrology : CJASN.

[3]  C. Ponticelli,et al.  Glomerular diseases: membranous nephropathy--a modern view. , 2014, Clinical journal of the American Society of Nephrology : CJASN.

[4]  Ľ. Podracká,et al.  [Practice guideline and trends for immunosuppressive treatment of glomerulonephritides according to KDIGO (Clinical Practice Guideline for Glomerulonephritis)]. , 2013, Vnitrni lekarstvi.

[5]  S. Chadban,et al.  Day-to-day variability in spot urine protein-creatinine ratio measurements. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  G. Remuzzi,et al.  Rituximab in idiopathic membranous nephropathy. , 2012, Journal of the American Society of Nephrology : JASN.

[7]  Jai Radhakrishnan,et al.  Notice , 2012, Kidney International Supplements.

[8]  David M. Beck,et al.  Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. , 2011, Journal of the American Society of Nephrology : JASN.

[9]  F. Cosio,et al.  Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[10]  克治 桑門.  海外論文紹介 : M-Type Phospholipase A2 Receptor as Target Antigen in Idiopathic Membranous Nephropathy , 2010 .

[11]  G. Fernández-Juárez,et al.  Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. , 2010, Journal of the American Society of Nephrology : JASN.

[12]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[13]  A. Kshirsagar,et al.  Rituximab therapy for membranous nephropathy: a systematic review. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[14]  M. Jardine,et al.  The Relationship between Proteinuria and Coronary Risk: A Systematic Review and Meta-Analysis , 2008, PLoS medicine.

[15]  H. Beanlands,et al.  The impact of sex in primary glomerulonephritis. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[16]  U. Specks,et al.  Idiopathic membranous nephropathy: diagnosis and treatment. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[17]  E. Bergstralh,et al.  Rituximab treatment of idiopathic membranous nephropathy. , 2008, Kidney international.

[18]  F. Breedveld,et al.  Rituximab Pharmacokinetics in Patients With Rheumatoid Arthritis: B‐Cell Levels Do Not Correlate With Clinical Response , 2007, Journal of clinical pharmacology.

[19]  K. Sud,et al.  A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. , 2007, Journal of the American Society of Nephrology : JASN.

[20]  J. Luño,et al.  Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. , 2007, Kidney international.

[21]  J. Scholey,et al.  Idiopathic membranous nephropathy: definition and relevance of a partial remission. , 2004, Kidney international.

[22]  J. López-Gómez,et al.  Clinicopathologic correlations of renal pathology in Spain. , 2004, Kidney international.

[23]  N. Yorioka,et al.  Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan. , 2004, Kidney international.

[24]  G. Remuzzi,et al.  Prognosis of untreated patients with idiopathic membranous nephropathy , 1993, Pediatric Nephrology.

[25]  L. Hebert,et al.  Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. , 2001, Kidney international.

[26]  M. Heller,et al.  An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. , 2000, Arthritis and rheumatism.

[27]  D. Cattran,et al.  Prognosis after a complete remission in adult patients with idiopathic membranous nephropathy. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[28]  A. Lupo,et al.  A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. , 1998, Journal of the American Society of Nephrology : JASN.

[29]  Guy Hoffman,et al.  Cyclophosphamide-Induced Cystitis and Bladder Cancer in Patients with Wegener Granulomatosis , 1996, Annals of Internal Medicine.

[30]  F. Locatelli,et al.  A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. , 1995, Kidney international.

[31]  A. Hagenbeek,et al.  Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. , 1995, Journal of the National Cancer Institute.

[32]  Y. Pei,et al.  Predicting progression in membranous glomerulonephritis. , 1992, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[33]  S. Garella,et al.  Use of single voided urine samples to estimate quantitative proteinuria. , 1983, The New England journal of medicine.